Site-specific conjugation of IgG with MMAE or PNU.

GlyCLICK is a site-specific conjugation technology for IgG using Fc glycan remodeling and click-chemistry. The technology generates stable and homogenous antibody conjugates for IgG from several species and subclasses. Fc-glycan remodeling by complete deglycosylation of the antibody allows for site-specific conjugation using robust click-chemistry, resulting in a degree of label (DOL) or drug-antibody ratio (DAR) of 2.

GlyCLICK ADC is available for site-specific labeling of 2 mg IgG with MMAE (Monomethyl auristatin E) or PNU (PNU anthracycline payload), and is suitable for the development of antibody-drug conjugates (ADCs).
 
MMAE is a potent cytotoxin that inhibits microtubule assembly and tubulin-dependent GTP hydrolysis, causing cell cycle arrest and apoptosis.
PNU is an anthracycline based DNA-alkylating toxin causing apoptosis with significantly higher potency that tubulin-targeting payloads.
 

• Site-specific payload-conjugation to IgG with a consistent drug-antibody ratio (DAR) of 2
• Unique linker payloads with a two-step enzymatic release mechanism
• Generates a site-specific ADC without antibody engineering
• Preserved immunoreactivity with greater control of cytotoxicity

Unit Definition

GlyCLICK ADC contains sufficient material for labeling of 2 mg IgG. For larger amounts or evaluation of the technology, please contact us.

Content and Storage

Components in GlyCLICK ADC:

• GlycINATOR Immobilized
• UDP-GalNAz
• GalT(Y289L)
• sDIBO (MMAE or PNU)
• All buffers needed
• Concentration and desalting columns

Content should be stored at different temperatures upon arrival.

FAQ and Support

Popular FAQ

Find all FAQ here